Tetrahedral Framework Nucleic Acids Loaded with Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma
Authors:
- 26 January 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 13 (5) , 6109-6118
Abstract
SiRNA is found to effectively knock down the target gene in cells, which is considered a promising strategy for gene therapy. However, the application of siRNA is limited due to its low efficiency of the cellular uptake. Tetrahedral framework nucleic acids (tFNAs) are synthesized by four single-stranded DNAs and show multiple biological functions in recent studies, especially suitable for drug delivery. More than 60% of malignant melanomas are associated with Braf gene mutation, an attractive therapeutic target for RNA interference. In this study, we modified anti-Braf siRNA (siBraf) with tFNAs to downregulate the target gene. Meanwhile, we directly incorporated AS1411 (a DNA aptamer) to our nanostructure, which assists tFNAs to improve the cellular uptake efficacy of siBraf significantly. The results indicated that tFNAs-AS1411-siBraf exhibited more potent activity to cleave Braf mRNA than free siBraf. This study may provide a new idea for the combination therapy of siRNA and aptamers via DNA nanomaterials to achieve gene silencing.Keywords
Funding Information
- National Natural Science Foundation of China (81970916, 81671031)
- National Key R&D Program of China (2019YFA0110600)
This publication has 57 references indexed in Scilit:
- Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystemNanomedicine: Nanotechnology, Biology and Medicine, 2018
- Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomasBiomaterials, 2014
- Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanomaBiomaterials, 2014
- Formulation Approaches to Short Interfering RNA and MicroRNA: Challenges and ImplicationsJournal of Pharmaceutical Sciences, 2012
- Potential clinical applications of siRNA technique: benefits and limitationsEuropean Journal of Clinical Investigation, 2010
- The promises and pitfalls of RNA-interference-based therapeuticsNature, 2009
- RNAi therapeutics: a potential new class of pharmaceutical drugsNature Chemical Biology, 2006
- Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature, 2001
- Role for a bidentate ribonuclease in the initiation step of RNA interferenceNature, 2001
- Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegansNature, 1998